 |
|
|
| |
SVR12 Rate of 96.2% in 209 HCV Genotype 1-infected Null Responders Treated With ABT-450/r/Ombitasvir and Dasabuvir With or Without Ribavirin
|
| |
| |
Reported by Jules Levin
AASLD 2014 Nov 7-11 Boston
Ira M Jacobson1, Jean-Francois DuFour2, Jeff rey Enejosa3, Robert J de Knegt4, Peter Ferenci5, Hendrik Reynaert6, Adrian M Di Bisceglie7, Lois Larsen3, Lino Rodrigues, Jr3, Thomas Podsadecki3, Donald Jensen8, Fred Poordad9
1Weill Cornell Medical College, New York, New York, United States; 2University Clinic for Visceral Surgery and Medicine, Bern, Switzerland; 3AbbVie Inc., North Chicago, Illinois, United States; 4Erasmus MC, Rott erdam, The Netherlands; 5Universitaetsklinik fuer Innere Medizin III, Vienna, Austria;
6Universitair Ziekenhuis Brussels, Brussels, Belgium; 7Saint Louis University Liver Center, Saint Louis University, St. Louis, Missouri, United States; 8Center for Liver Diseases, University of Chicago Medical Center Chicago, Chicago, Illinois, United States; 9The Texas Liver Insti tute/University of Texas
Health Science Center, San Antonio, Texas, United States
|
| |
|
|
|
|
|
